Instil Bio, Inc. 8-K

What Happened Instil Bio, Inc. (TIL) filed a Form 8‑K on May 15, 2026 (Item 2.02) to provide a corporate update and announce its financial results for the quarter ended March 31, 2026. The company attached a press release dated May 15, 2026 as Exhibit 99.1, which is incorporated by reference into the filing. The 8‑K was signed by Sandeep Laumas, M.D., the company’s Chief Financial Officer and Chief Business Officer.

Key Details

• Filing date: May 15, 2026 (Form 8‑K Items 2.02 and 9.01).
• Reporting period: Quarter ended March 31, 2026.
• Disclosure vehicle: Press release dated May 15, 2026 filed as Exhibit 99.1 (contains the detailed financial results).
• Administrative note: The cover page of the report is formatted in Inline XBRL; the filing was signed by CFO Sandeep Laumas.

Why It Matters This 8‑K signals that Instil Bio has publicly released its latest quarterly results and a corporate update — items that can affect near‑term investor decisions. The Form 8‑K itself summarizes the event but refers readers to the attached press release for the actual financial figures, revenue, operating results, cash position and any forward guidance. Investors should read the Exhibit 99.1 press release and any subsequent filings or investor materials (earnings slides or call transcript) to assess revenue trends, expenses, cash runway and clinical/program updates that could drive the stock.